SLC34A2 and hepatocellular carcinoma: However, HCC-78 cells expressing WT SLC34A2-ROS1 fusion protein, NCI-H1975 cells with EGFRL858R/T790M and NIH-3T3 cells with CD74-ROS1 expressed rendered resistance to iruplinalkib and brigatinib (IC50, 227.6–508 nM; Fig. 1c).